TCI Wealth Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

TCI Wealth Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-20	Closed	-$3K	–	2480
2021 Q2	$3K	Buy	+20	New	+$2.9K	﹤0.01%	1780

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

DMPV

Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCI Wealth Advisors's KPTI Position: Q3 2021 in Review

TCI Wealth Advisors sold out of Karyopharm Therapeutics (KPTI) in Q3 2021, closing a stake of 20 shares — an estimated $3K sold.

TCI Wealth Advisors first reported a position in KPTI in Q2 2021 and held it in 1 quarter. The position peaked at $3K in Q2 2021. 134 funds tracked by Wall St. Rank hold KPTI as of Q3 2021.

TCI Wealth Advisors reported no remaining Karyopharm Therapeutics position as of Q3 2021 after selling out during the quarter.
TCI Wealth Advisors sold 20 Karyopharm Therapeutics shares in Q3 2021, an estimated $3K.
TCI Wealth Advisors first reported a position in Karyopharm Therapeutics in Q2 2021 and held it in 1 quarter.
TCI Wealth Advisors's Karyopharm Therapeutics position peaked at $3K in Q2 2021.
134 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2021.

Based on TCI Wealth Advisors's 13F filing for Q3 2021, filed 29 Oct 2021.